Company Summary
Search
Home Page
 
Immunovaccine Inc. 
Listed Company 
Current   Past  
Fiscal Year EndCompany StatusExempt Flag
December 31TradingN
Board of Directors
NamePosition
Albert Scardino  Executive chairman
  Director of the Board
Brad Thompson  Director of the Board
James Willis Hall  Director of the Board
John J. Trizzino  Director of the Board
Llew Keltner  Director of the Board
Marc Mansour  Director of the Board
Not Applicable (None)  President
Stephanie Leouzon  Director of the Board
Wade K. Dawe  Director of the Board
Wayne Pisano  Director of the Board
Incorporation Locations
Inc. DateExpiry DateCountryRegionDescription
18/May/2007  Canada   
Exchange Filing Office
Location
Montreal Regional Service Office
Business Type(s)
Primary/SecondaryBusiness TypeDetails
Primary  Research and Development in the Physical, Engineering and Life Sciences  From News Release May 1, 2013 - Immunovaccine Inc. applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company's DepoVax(TM) platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax(TM)-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious diseases pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at www.imvaccine.com. 
Securities
SymbolSecurity NameMarketStatus
IMVImmunovaccine Inc.TSX VentureTRADING
Name HistoryFromTo
Immunovaccine Inc.5/Oct/2009Present
Company Facts Reconciliation
SubjectDate Returned
Summer 2013 CFR30/Jul/2013
Associations
Auditing Firm:  PricewaterhouseCoopers LLP
Sponsor:  Macquarie Private Wealth Inc.
Transfer Agent:  Computershare Investor Services Inc.
Latest Information
TypeDateTitle
News Releases  24/Apr/2014  NEWS RELEASE - RESULTS OF 2014 ANNUAL GENERAL MEETING[MARKET NEWS]
    NEWS RELEASE - IMMUNOVACCINE ANNOUNCES RESULTS OF 2014 ANNUAL GENERAL MEETING[MARKETWIRE]
    NEWS RELEASE - IMMUNOVACCINE'S DEPOVAX(TM) TECHNOLOGY UNDERPINS NEW EXPERIMENTAL THERAPY FOR CERVICAL HEAD AND NECK CANCERS[MARKETWIRE]
Bulletins  5/Dec/2013  PP-N-B
Meetings and Public Filings  Information on financial statements, public filings and corporate meetings for all Canadian public companies can be found at www.sedar.com
Property Locations
(not available)

* Historical Data